Amphetamines, Serum or Plasma, Quantitative
2010066
Ordering Recommendation
Detect exposure to amphetamines.
Mnemonic
AMPS SP
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Tue
Reported
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
- Patient Preparation
- Collect
- Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).
- Specimen Preparation
- Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.
- Remarks
- Stability
- After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years
Reference Interval
Effective August 17, 2015
| Drugs Covered | Cutoff Concentrations |
| Amphetamine | 20 ng/mL |
| Methamphetamine | 20 ng/mL |
| Methylenedioxyamphetamine (MDA) | 20 ng/mL |
| Methylenedioxymethamphetamine (Ecstasy, MDMA) | 20 ng/mL |
| Methylenedioxyethylamphetamine (Eve, MDEA) | 20 ng/mL |
Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Positive cutoff: 20 ng/mL
For medical purposes only; not valid for forensic use.
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
Positive cutoff: 20 ng/mL
For medical purposes only; not valid for forensic use.
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
Hotline History
N/A
CPT Code(s)
80324; 80359 (Alt code: G0480)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2010068 | Amphetamine, S/P, Quant | 30112-7 |
| 2010069 | Methamphetamine, S/P, Quant | 3778-8 |
| 2010070 | MDA, S/P, Quant | 59837-5 |
| 2010071 | MDMA, S/P, Quant | 18356-6 |
| 2010072 | MDEA, S/P, Quant | 33016-7 |
Aliases
- Adderall
- Amphetamine
- Benzedrine
- Carbex
- Deprenyl
- Desoxyephedrine
- Desoxyn
- Dexedrine
- Dextroamphetamine
- Ecstasy
- Eldepryl
- Emsam
- Eve
- Lisdexamfetamine
- MDA
- MDEA
- MDMA
- Methamphetamine
- Methedrine
- Pain Management
- Paremyd
- Selegiline
- Vicks Inhaler
- Vynase
- XTC
- Zelapor